SCHEMBL22342193

SCHEMBL22342193

CCc1ccccc1-c1ccccc1CSC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
CSNK2A3 Q8NEV1 1/20 0.42
CYP2D6 P10635 1/20 0.39
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
DHFR P00374 1/20 0.36
EGFR P00533 1/20 0.36
TRPA1 O75762 1/20 0.36
KCNN4 O15554 1/20 0.36
MAP2K7 O14733 1/20 0.35
CDC25A P30304 1/20 0.35
CDC25B P30305 1/20 0.35
MGLL Q99685 1/20 0.35
LMNA P02545 2/20 0.35
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13560718 0.84 GABRA1 (0.42) CYP2D6GABRA1GABRB2EGFRMGLL
SCHEMBL198461 0.83 CSNK2A2 (0.52) CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6
SCHEMBL2776956 0.81 CSNK2A2 (0.50) CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6
Ethane SCHEMBL3687850 0.81 CSNK2A2 (0.50) CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6
SCHEMBL11382359 0.81 CSNK2A2 (0.50) CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6
SCHEMBL22342192 0.81 FFAR1 (0.40) ALOX5APFEN1EGFRLMNANPC1
SCHEMBL15912540 0.79 MAPK1 (0.42) CYP2D6ALOX5APFEN1EGFRLMNA
SCHEMBL2208060 0.78 DPP4 (0.54) ALOX5APFEN1LMNAALDH1A1MAPK1
SCHEMBL3083039 0.78 MAPT (0.39) CYP2D6GABRA1GABRB2ALOX5APFEN1
SCHEMBL24042759 0.77 KDM4E (0.44) CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200255478-A1 NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY ALMIRALL SA (ES) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255478-A1 NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY KEAP1, NFE2L2, HMOX1 CSNK2A2 2092/4885CSNK2B 2210/4885CSNK2A1 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.